In contrast, the lncRNA-XIST/miR-137 axis can enhance CRC glycolysis and chemotherapy resistance, providing a possible alternative to improve chemotherapy efficacy in CRC patients (110). The gene discussed is XIST; the disease is colorectal carcinoma.